Search
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnSomatostatin, also known as growth hormone-inhibiting hormone, is a naturally-occurring peptide hormone of 14 or 28 amino acid residues that regulates the endocrine system. It is secreted by the D cells of the islets to inhibit the relea...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsDaclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnDaclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection. It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydroch...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesMedrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnMedrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option. It was developed by Ay...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substratesp-Fluorofentanyl
go.drugbank.com/drugs/DB09177ExperimentalIllicitp-Fluorofentanyl is an opioid analgesic being an analogue of fentanyl developed by Janssen Pharmaceutica in the 1960s. p-Fluorofentanyl was sold briefly on the US black market in the early 1980s, before … introduction of the Federal Analog Act which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared. p-Fluorofentanyl
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnViloxazine is a selective norepinephrine reuptake inhibitor. For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-releas...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsLorpiprazole
go.drugbank.com/drugs/DB09195ApprovedLorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesNetoglitazone
go.drugbank.com/drugs/DB09199ExperimentalNetoglitazone (MCC-555) is a hypoglycemic agent.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsSynephrine
go.drugbank.com/drugs/DB09203InvestigationalSynephrine, also referred to as, p-synephrine, is naturally occurring alkaloid. … It is present in approved drug products as neo-synephrine, its m-substituted analog. p-synephrine and m-synephrine are known for their longer acting adrenergic effects compared to norepinephrine.
Synonyms: p-synephrineArotinolol
go.drugbank.com/drugs/DB09204InvestigationalArotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy. Artinolol is being developed by Sumito...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates